Life Sciences Archives - Page 4 of 22 - Becker's Hospital Review

Stopping GLP-1s tied to 22% rise in heart attacks | Pfizer's Lyme vaccine heads to FDA | Eli Lilly's new GLP-1 cuts weight, A1C | Novel hemophilia gene therapy debuts in Detroit | FDA recalls 89K ibuprofen bottles

GLP-1 risks, a Lyme vaccine, gene therapy debut and an ibuprofen recall in focus. March 25, 2026 1. Stopping GLP-1s linked to 22% rise in heart attack: 5 study notes Full story 2. Pfizer Lyme vaccine candidate heads to FDA…

HHS eyes $200M cancer vaccine push | Senate probes FDA drug denials | Novo missed adverse event reports | Demand grows for unproven autism drug | 3 GLP-1 updates

HHS eyes $200M cancer vaccine effort as FDA faces Senate probe. March 18, 2026 1. HHS plans $200M cancer vaccine initiative: Wall Street Journal Full story 2. Clinicians divided amid growing demand for unproven autism drug Full story 3. Reviewer…

Cancer drug pulled from US market | GLP-1s linked to lower addiction risk | FDA, states review plans to import drugs | Novo, Hims strike GLP-1 deal after legal feud | PE invests $1 trillion in healthcare in a decade

A new GLP-1 study, a cancer drug pulled from the US market and Novo strikes a deal with Hims. March 11, 2026 1. Cancer drug pulled from US market Full story 2. GLP-1 drugs tied to lower addiction risk: Study…

Cancer drug trial paused after death | Novo Nordisk inks $2B obesity drug deal | GLP-1s tied to higher osteoporosis risk | Intellia trial hold lifted | 12 drugs in shortage

Trial pause after patient death, a $2B obesity drug deal and new GLP-1 safety concerns. March 4, 2026 1. Novo Nordisk inks $2.1B oral obesity drug deal Full story 2. FDA partially pauses cancer drug trial after patient death Full…

Bayer sues J&J over cancer drug claims | Zepbound tops Novo Nordisk's GLP-1 in trial | FDA to drop 2-study rule | Schizophrenia, bipolar pill wins FDA OK | 6 healthcare notes from Trump's State of the Union

Drugmaker legal clash, GLP-1 data and FDA policy change. February 25, 2026 1. Bayer sues J&J over prostate cancer drug claims Full story 2. Trump's State of the Union: 6 healthcare takeaways Full story 3. 3,500 healthcare executives. 795 speakers.…

FDA reverses course on Moderna flu vaccine review | Biosimilar OK'd for chemo infection risk | Huntsman to manufacture 1st imaging drug in US | 5 notes on GLP-1s, cancer risk

FDA actions, GLP-1 data and a 1st-in-US drug manufacturing move. February 18, 2026 1. FDA reverses course; agrees to review Moderna flu vaccine Full story 2. Another win for GLP-1s and cancer risk: 5 study notes Full story 3. 2026…

War breaks out over GLP-1 pills | FDA refuses review of Moderna flu vaccine | Amgen won't withdraw rare disease drug | 4 drug candidates to watch

Regulatory setback for Moderna, Amgen stands firm, plus 4 pipeline drugs to watch. February 11, 2026 1. FDA refuses to review Moderna flu vaccine Full story 2. War breaks out over GLP-1 pills Full story 3. How will healthcare's new…

Breast cancer drug gets FDA priority review | FDA eyes boost to US drug manufacturing | Eli Lilly plans $3.5B injectable site | GLP-1s drive 79% pharma M&A surge | Penn State sues PBMs over pricing scheme

FDA actions, pharma investments and deals impacting life sciences. February 4, 2026 1. FDA grants priority review to breast cancer drug Full story 2. FDA delays approval of AstraZeneca's injectable lupus drug Full story 3. Margins, power brokers & site-of-care…

Texas AG probes vaccine incentives | Lilly inks $1.1B gene therapy deal | FDA lifts Intellia trial hold | Future GLP-1s may be gene therapies | Velsera names CEO

Gene therapy momentum builds: deals, trials and GLP-1s. January 28, 2026 1. Texas attorney general probes alleged immunization 'incentives': 4 vaccine updates Full story 2. Lilly inks $1.1B gene therapy deal for hearing loss Full story 3. 2026 strategy check:…

Eli Lilly, Novo Nordisk sued over GLP-1 access | FDA fast-tracks Parkinson’s cell therapy | 8 notes on bipartisan health package | FDA delays 2 priority drug reviews | Cedars-Sinai builds AI drug safety tool

FDA actions, GLP-1 access fight and an AI drug safety push. January 21, 2026 1. Compounding pharmacy sues Eli Lilly, Novo Nordisk over GLP-1 access Full story 2. FDA fast-tracks novel Parkinson's cell therapy Full story 3. Drug shortages are…